bioMérieux is a global leader in in vitro diagnostics and provides diagnostics solutions that improve patient health and ensure consumer safety.

* Sofina is represented in the decision-making bodies of the company.


Healthcare and life sciences

Shareholding percentage


Sales on 31/12/2022

EUR 3.6 bn



Systems installed worldwide


International presence

160 countries
45 subsidiaries

The history of the group dates back to 1890, when Marcel Mérieux developed an array of vaccines and biological products. bioMérieux, worldwide actor in the field of in vitro diagnostics, is the world leader in microbiological detection diagnostic solutions for clinical and industrial (agri-food, biopharma and cosmetics) applications as well as in the field of molecular syndromic testing for infectious diseases. The clinical diagnostics solutions detect and quantify the presence of disease agents as well as substances secreted by the human body. The industrial microbiological control solutions provide microbiological tests throughout the production process and check among others for the absence of pathogenic bacteria or microorganism that could affect the quality of the products.

Since its creation, the group is controlled by Institut Mérieux and is currently run by the fourth generation of the Mérieux family.

Investment history

France | 2009

bioMérieux is headquartered in Marcy-l’Etoile, France. The teams of Sofina and Institut Mérieux know each other since 2003, six years before the investment, which allowed the creation of a strong trust relationship ahead of the investment of 2009. Since then, the relationship has strengthened through the participation at meetings of the board and the audit committee chaired by the board member nominated by Sofina.